Table 4.

Systemic review of previous studies on receptor discordance between primary breast cancer and brain metastases

	Markers	No. of cases	Positive conversion	Negative conversion	Total
Gaedcke et al. [16]	ER	23	2	4	6 (26.1%)
	PR	23	2	3	5 (21.7%)
	HER2	23	2	1	1 (4.2%)
Yonomori et al. [17]	ER	24	2	2	4 (16.7%)
	PR	24	0	1	1 (4.2%)
	HER2	24	1	2	3 (12.5%)
Omoto et al. [9]	ER	21	2	2	4 (19.0%)
	PR	21	1	3	4 (19.0%)
	HER2	21	3	1	4 (19.0%)
Hoefnage et al. [7]	ER	44	NA	NA	6 (13.6%)
	PR	44	NA	NA	16 (36.4%)
	HER2	44	NA	NA	1 (2.3%)
Shao et al. [18]	ER	18	0	1	6 (16.2%)
	PR	18	4	4	8 (44.4%)
	HER2	18	1	0	1 (5.6%)
Brogi et al. [4]	ER	37	NA	NA	6 (16.2%)
	PR	39	NA	NA	8 (20.5%)
	HER2	40	0	2	2 (5.0%)
Duchnowska et al. [10]	ER	120	13	22	35 (29.2%)
	PR	119	11	18	29 (24.4%)
	HER2	119	10	7	17 (14.3%)
Total	ER	287			62 (21.6%)
	PR	288			71 (26.7%)
	HER2	289			31 (10.7%)

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, NA not applicable